Zhengye Biotechnology Holding Limited, a prominent player in the health care sector, has been making significant strides in the field of veterinary vaccines. As a subsidiary of Securingium Holding Limited, Zhengye Biotechnology has established itself as a key entity in the research, development, manufacture, and sale of vaccines for livestock within the People’s Republic of China. The company’s comprehensive portfolio includes vaccines for a wide range of animals, such as swine, cattle, goats, sheep, poultry, and dogs. Notably, their offerings encompass monovalent, polyvalent, combined, and combined and polyvalent vaccines, addressing various health needs within the livestock industry.
In addition to livestock vaccines, Zhengye Biotechnology is also at the forefront of developing vaccines for household animals. Their product line includes the rabies vaccine and Strain Flury LEP for dogs, catering to the growing demand for pet health solutions. This diversification underscores the company’s commitment to enhancing animal health across different sectors.
Zhengye Biotechnology’s influence extends beyond domestic borders, with its products being exported to countries such as Vietnam, Pakistan, and Egypt. This international reach highlights the company’s capability to meet global standards and its strategic positioning in the global market. The company’s clientele includes direct-end customers like livestock farmers and local governments, as well as domestic and exporting distributors, ensuring a broad and diverse customer base.
Despite facing challenges reflected in its financial metrics, such as a negative price-to-earnings ratio of -3.59 and a recent close price of $8.01 on July 19, 2026, Zhengye Biotechnology’s market capitalization stands at approximately $33,079,182 USD. The company’s stock has experienced significant volatility, with a 52-week high of $13.08 on September 1, 2025, and a low of $0.616 on July 1, 2026. These fluctuations indicate the dynamic nature of the biotechnology sector and the external factors influencing market performance.
Founded in 2004 and headquartered in Jilin, China, Zhengye Biotechnology has demonstrated resilience and adaptability over the years. As the company continues to innovate and expand its product offerings, it remains a vital contributor to the health care sector, particularly in the realm of veterinary medicine. With its strategic focus on both domestic and international markets, Zhengye Biotechnology is well-positioned to navigate future challenges and capitalize on emerging opportunities in the global veterinary vaccine industry.
